m6A methylation regulators as predictors for treatment of advanced urothelial carcinoma with anti-PDL1 agent

PURPOSE: Immune checkpoint blockade agents were shown to provide a survival advantage in urothelial carcinoma, while some patients got minimal benefit or side effects. Therefore, we aimed to investigate the prognostic value of m6A methylation regulators, and developed a nomogram for predicting the r...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Jianqiu, Lu, Sihong, Zhang, Long, Yao, Yuhui, Zhang, Jie, Shen, Zefeng, Luo, Mingli, Liu, Bin, Zheng, Junjiong, Lin, Tianxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521425/
https://www.ncbi.nlm.nih.gov/pubmed/36189296
http://dx.doi.org/10.3389/fimmu.2022.1014861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521425/
https://www.ncbi.nlm.nih.gov/pubmed/36189296
http://dx.doi.org/10.3389/fimmu.2022.1014861

Ejemplares similares